Home Blog Page 1612

Nature Communications | Insilico Medicine Presents AI-empowered Dual-Action PROTAC Targeting PKMYT1

By
Advertorial Desk
-
  • AI Designs a Novel RPOTAC from Scratch: Insilico’s generative AI platform, Chemistry42, successfully designed a first-in-class PROTAC targeting PKMYT1 by creating an entirely new inhibitor and its complex linker, demonstrating a powerful, end-to-end approach to new modality drug discovery.
  • A Superior Dual-Action Mechanism: The novel PROTAC, D16-M1P2, employs a powerful dual-action mechanism that simultaneously degrades and inhibits the cancer-driving PKMYT1 protein, resulting in a more potent, selective, and durable therapeutic effect than traditional inhibitors.
  • Strong Preclinical Results Move Therapy Forward: The AI-designed PROTAC delivered potent anti-tumor activity with high selectivity and favorable oral bioavailability in preclinical studies and has now advanced to the pre-candidate validation stage.

CAMBRIDGE, Mass., Dec. 2, 2025 /PRNewswire/ — PKMYT1 (Membrane-associated Tyrosine/Threonine Protein Kinase 1) is a serine/threonine protein kinase that plays a pivotal role in cell cycle regulation. Previous studies have shown that inhibiting PKMYT1 through a synthetic lethality approach allows for the selective elimination of cancer cells bearing specific genetic mutations, such as CCNE1 amplification or mutations in FBXW7 and PPP2R1A, while sparing normal healthy cells and minimizing adverse effects. It makes PKMYT1 a promising therapeutic target for biomarker-defined patient populations.

However, existing PKMYT1 inhibitors face significant limitations, including insufficient molecular diversity and poor selectivity, which can lead to off-target effects and dose-limiting toxicity in clinical trials. Additionally, concerns about acquired resistance arising from mutations in cancer cells further complicate inhibitors’ efficacy. Research also indicates that PKMYT1 has important non-catalytic functions, such as stabilizing β-catenin and activating Wnt signaling, which are not addressed by conventional inhibitors. These challenges underscore the need for new therapeutic strategies that can more effectively and safely target PKMYT1 in cancer.

In a recent pioneering study, researchers at Insilico Medicine (“Insilico”), a generative artificial intelligence (AI)-driven clinical-stage biotechnology company, harnessed its AI-driven generative chemistry platform, Chemistry42, to design a novel, first-in-class PROTAC targeting PKMYT1, D16-M1P2, which employs a dual mechanism of action—inducing PKMYT1 degradation while directly inhibiting its kinase activity. This innovative strategy holds promises for overcoming limitations of existing inhibitors, such as poor selectivity and acquired resistance, and to effectively target both the catalytic and non-catalytic functions of PKMYT1. As a result, the PROTAC demonstrates the potential for a more selective, potent, and durable therapeutic effect.

Published in Nature Communications, this work highlights the powerful capabilities of Insilico’s AI-driven generative chemistry and serves as a compelling example of its ability to guide complex, multi-component drug design.

The process of discovery began with the design of PKMYT1 inhibitors. Researchers at Insilico utilized the Chemistry42 AI platform to design a novel PKMYT1 inhibitor by integrating the pharmacophore features of two established kinase inhibitors. Guided by over 40 AI models within Chemistry42, they generated 2,023 novel molecules. A thorough filtering process—assessing novelty, binding interactions, and drug-like properties—identified the most promising candidate, which was subsequently synthesized as compound 1.

Subsequently, the team systematically optimized compound 1 through structure-based design and medicinal chemistry. This iterative process enhanced its potency and pharmacokinetic properties, ultimately yielding compound 4—an inhibitor with excellent kinase selectivity that provided an ideal attachment point for PROTAC development.

After obtaining the optimized inhibitor, the team constructed a 3D virtual model of the PKMYT1–PROTAC–CRBN ternary complex to determine optimal linker parameters. Leveraging the Chemistry42 AI platform, they generated novel linkers to connect compound 4 to the E3 ligase, ultimately synthesizing the first-generation PROTAC, D1. Through subsequent evaluation and modification, the PROTACs were further optimized for solubility, clearance, and oral exposure, leading to the development of D16-M1P2 as the final lead candidate.

The lead PROTAC, named D16-M1P2, demonstrated promising performance in preclinical studies.It exhibited remarkable selectivity, inhibiting only 4 out of 403 kinases tested, which resulted in potent anti-tumor activity in xenograft models as well as favorable oral bioavailability across multiple preclinical species. Compared to traditional PKMYT1 inhibitors, D16-M1P2 induces more durable and sustained effects by targeting PKMYT1 for complete degradation through the ubiquitin-proteasome system, with activity maintained for at least 24 hours after drug removal. Additionally, D16-M1P2 offers a dual mechanism of action: it primarily degrades PKMYT1 but also directly inhibits residual kinase activity at higher concentrations, ensuring comprehensive pathway suppression.

“The dual-mechanism of D16-M1P2, combining potent degradation with kinase inhibition, offers a multi-pronged attack on a critical cell cycle regulator in cancer,” said Feng Ren, PhD, co-CEO and Chief Scientific Officer of Insilico Medicine. “Its high selectivity and sustained pharmacodynamic effects observed in preclinical studies suggest it could overcome the safety and efficacy limitations of previous PKMYT1 inhibitors. This molecule serves as both a powerful chemical probe to study PKMYT1 biology and a promising new therapeutic candidate.”

The research team has now advanced D16-M1P2 to the Pre-Candidate (Pre-PCC) validation stage. Previously, Insilico published the design and optimization process of the PKMYT1 inhibitor series from this program in the JMC in February 2025. Building on this foundation, the new research upgrades the modality from small molecules to PROTACs, achieving further improvements in selectivity, safety, and efficacy. This study also exemplifies how AI tools can adeptly navigate the complexities of PROTAC design—spanning inhibitor design to linker optimization —pioneering new directions in AI-driven drug discovery.

“This paper is a clear demonstration of our AI platform’s ability to innovate beyond conventional small molecules and tackle next-generation therapeutic modalities like PROTACs,” said Alex Zhavoronkov, PhD, founder and co-CEO of Insilico Medicine. “By generating both the novel warhead and the optimal linker, we have shown that AI can be an invaluable partner in designing highly specific, multi-functional drugs for challenging cancer targets.”

Since its inception, Insilico has published over 200 peer-reviewed papers. This marks the sixth publication by the company in Nature Portfolio journals since 2024. Leveraging sustained scientific breakthroughs at the intersection of biotechnology, artificial intelligence, and automation, Insilico ranked Top 100 global corporate institutions in Nature Index‘s “2025 Research Leaders: global corporate institutions for biological sciences and natural sciences publications”.

Harnessing state-of-the-art AI and automation technologies, Insilico has significantly improved the efficiency of preclinical drug development, setting a benchmark for AI-driven drug R&D. While traditional early-stage drug discovery typically requires 2.5 to 4 years, Insilico has nominated 20 preclinical candidates with an average timeline—from project initiation to preclinical candidate (PCC) nomination—of just 12 to 18 months per program, with only 60 to 200 molecules synthesized and tested in each program.

About Insilico Medicine

Insilico Medicine, a leading and global AI-driven biotech company, utilizes its proprietary Pharma.AI platform and cutting-stage automated laboratory to accelerate drug discovery and advance innovations in life sciences research. By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine. For more information, please visit www.insilico.com.

 

Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities

By
Advertorial Desk
-

SYDNEY, Dec. 2, 2025 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced that it has entered into a securities purchase agreement with certain established institutional and accredited investors for a private placement of equity securities (PIPE). Pursuant to the securities purchase agreement, the Company agreed to offer and sell to the investors an aggregate of approximately $50.0 million of ordinary shares and prefunded warrants, at a purchase price per share that is the equivalent of $5.00 per ADS, each ADS representing 500 ordinary shares. The PIPE is structured as a straightforward equity investment with no common warrant coverage. The PIPE financing was led by healthcare-dedicated investors including Adar1 Capital Management LLC, Ikarian Capital LLC, Stonepine Capital Management, Velan Capital Investment Management LP, and Revach Capital Management, LLC, alongside existing shareholders, including Jorey Chernett. The transaction is expected to close on Wednesday, December 3, 2025, subject to customary closing conditions.

Konik Capital Partners, LLC is acting as the exclusive placement agent for the PIPE.

The net proceeds to the Company from the PIPE are expected to be approximately $46.5 million, after deducting placement agent’s fees and other estimated offering expenses payable by the Company. The Company currently intends to use the net proceeds from the offering, together with its existing cash, cash equivalents and marketable securities, to support the continued clinical development of its lead program paxalisib, a brain-penetrant dual PI3K/mTOR inhibitor currently in clinical trials for both brain cancer and advanced breast cancer, advancing the PD-L1 degrader program, and for general corporate purposes. The Company expects the net proceeds from the PIPE, combined with the existing cash and cash equivalents, will extend its cash runway into the second half of 2028.

The securities sold in this PIPE are being made in a transaction not involving a public offering and have not been registered under the Securities Act of 1933, as amended, or applicable state securities laws, and may not be offered or sold in the United States absent an effective registration statement or an applicable exemption from registration requirements. Pursuant to the securities purchase agreement, the Company has agreed to file a shelf registration statement with the U.S. Securities and Exchange Commission (SEC) within 30 days of the closing to register the resale of ADSs representing the ordinary shares and those underlying the pre-funded warrants.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offering of the securities described above under the resale registration statement will only be by means of a prospectus.

About Kazia Therapeutics Limited

Kazia Therapeutics Limited (NASDAQ: KZIA) is an innovative oncology-focused drug development company, based in Sydney, Australia. Our lead program is paxalisib, a brain-penetrant pan-PI3K/mTOR inhibitor, which is being developed to treat multiple forms of brain cancer, including glioblastoma and brain metastases. A Phase 1b clinical trial is also underway evaluating paxalisib in combination with checkpoint inhibition and chemotherapy for patients with advanced triple-negative breast cancer. EVT801, a selective VEGFR3 inhibitor, is currently in a Phase 1 clinical trial for advanced solid tumors. Kazia is working to rapidly progress these assets through clinical development and toward commercialization.

Forward Looking Statements

This announcement may contain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, which can generally be identified as such by the use of words such as “may,” “will,” “estimate,” “future,” “forward,” “anticipate,” or other similar words. Any statement describing Kazia’s future plans, strategies, intentions, expectations, objectives, goals or prospects, and other statements that are not historical facts, are also forward-looking statements, including, but not limited to, statements regarding: the completion of the PIPE, the satisfaction of customary closing conditions related thereto, the intended use of proceeds from the PIPE, the anticipated extension of the Company’s cash runway into the second half of 2028 following completion of the PIPE, and the Company’s future expectations, plans and prospects. Such statements are based on Kazia’s current expectations and projections about future events and future trends affecting its business and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including risks and uncertainties: related to market and other conditions, associated with clinical and preclinical trials and product development, including the risk that preliminary or interim data may not reflect final results, related to regulatory approvals, and related to the impact of global economic conditions. These and other risks and uncertainties are described more fully in Kazia’s most recent Annual Report, filed on form 20-F with the SEC, and in subsequent filings with the SEC. Kazia undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required under applicable law. Investors should not place undue reliance on these forward-looking statements, which apply only as of the date of this announcement.

For further information contact:

Alex Star
Managing Director
LifeSci Advisors LLC
Astarr@lifesciadvisors.com
Ph: +1 (201) 786-8795

Neurophet Appoints Josh Cohen, Former Executive from a Global Medical AI firm, as Head of Americas Business — To Accelerate U.S. Market

By
Advertorial Desk
-
  • Expert in sales and commercial strategy…Ex-Philips and previously served as Chief Commercial Officer (CCO) at Cortechs.ai
  • To strengthen revenue growth of AI-based brain imaging solutions in the North American market and expand product deployment across healthcare institutions

SEOUL, South Korea, Dec. 2, 2025 /PRNewswire/ — Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, announced on 2nd that it has appointed Josh Cohen, a veteran executive from leading global medical device companies, as new Head of Americas Business.

Josh Cohen, Head of Americas Business at Neurophet
Josh Cohen, Head of Americas Business at Neurophet

Josh Cohen, newly appointed Head of Americas, brings over a decade of expertise in sales and commercialization strategy within the medical AI sector. He has honed his skills through leadership roles in global sales and marketing at top-tier medical device companies, including Philips—one of the world’s leading medical imaging manufacturers—as well as Cortechs.ai, Shared Imaging, and most recently has worked as the acting Chief Commercial Officer (CCO) with MRI AI-based technology companies to launch and scale in the US and abroad.

Josh Cohen previously served as CCO at Cortechs.ai, one of Neurophet’s global rivals, where he spearheaded the growth of key AI-driven brain imaging analysis products and led the company’s expansion across international markets. Cortechs.ai specializes in AI-based medical imaging analysis software and directly competes with Neurophet in the Americas region.

Neurophet, market leader in the Asia Pacific region, is now focused on accelerating its entry into the Americas with this key appointment. Having led the execution of global commercialization strategies at a leading AI brain imaging analysis company, Josh Cohen will now build the team, the operations, and the customer success for Neurophet in the Americas.

With patients, clinicians, and customer satisfaction at the forefront, Neurophet aims to drive revenue growth, establish distribution partnerships, and implement market entry strategies across Canada, the United States, and South America.

Josh Cohen, Head of Americas Business at Neurophet, stated “I am delighted to be part of Neurophet, a company with global competitiveness in the field of imaging analysis related to Alzheimer’s disease treatment prescriptions and look forward to accelerating product sales by strengthening our entry into the North American market.”

Jake Junkil Been, Co-CEO of Neurophet, said “With Josh Cohen joining us, the pivotal leader behind the rapid growth of our key competitor Cortechs.ai, Neurophet is well-positioned to accelerate product deployment throughout the North American market. Looking ahead, we aim to expand our product offerings with a strong focus on major healthcare institutions across the United States.”

About Neurophet

Neurophet specializes in developing solutions for diagnosis support, treatment guides, and treatment devices targeting brain disorders based on cutting-edge artificial intelligence (AI) technology. The company was founded in 2016 by Co-CEOs Jake Junkil Been and Donghyeon Kim, who developed the next-generation neuro-navigation system.

Major products include brain MRI analysis software “Neurophet AQUA”, PET Image Quantitative Analysis Software “Neurophet SCALE PET”, Brain imaging treatment planning software for electric and magnetic brain stimulation “Neurophet tES/TMS LAB”, Alzheimer’s Disease treatment prescription and monitoring software “Neurophet AQUA AD” for tracking treatment efficacy and side effects, and Multiple Sclerosis image analysis software “Neurophet AQUA MS”.

Neurophet has set its top priority to helping patients suffering from brain disorders. Based on expertise in neuroscience, Neurophet will continue to challenge and grow to explore the human brain’s health and pioneer solutions for brain diseases with AI technology.

 

SPC Group’s Paris Baguette expands its global store count to 700, adding a new location in Westfield London

By
Advertorial Desk
-
  • The new milestone came only 13 months after the opening of the 600th store
  • Paris Baguette is aggressively expanding its franchise footprint in Europe, building on its success in the US and China
  • The multi-unit franchise operation demonstrates the brand’s competitiveness and franchise partnership
  • Paris Baguette is scheduled to open its third franchise location near Portobello Market at end-2025

SEOUL, South Korea, Dec. 2, 2025 /PRNewswire/ — Paris Baguette, the global bakery-café franchise under the SPC Group, is adding a new location in Westfield, expanding its global store count to 700. The new milestone came only 13 months after the company celebrated the opening of its 600th store in mid-October 2024.

Paris Baguette Westfield, the 700th global location
Paris Baguette Westfield, the 700th global location

Paris Baguette Westfield is Paris Baguette’s fourth location and second franchise store in the UK, reflecting the company’s success in expanding its franchise footprint beyond the US and China to Europe. Paris Baguette’s first franchise store in Canary Wharf has experienced a steady inflow of customers since the opening in November 2024, establishing a compelling presence in the UK market. Paris Baguette Canary Wharf is now well positioned to thrive, aided by a high repeat purchase rate. Notably, the Westfield location is opened by the owner of the first Paris Baguette franchise store. The multi-unit franchise operation demonstrates Paris Baguette’s solid brand competitiveness and franchise partnership.

The Westfield store is located on the ground floor of Westfield London, a large shopping mall in the Shepherds Bush area of west London. With hundreds of global brands across luxury goods, fashion, lifestyle and home appliance categories, Westfield London is one of the biggest shopping centers in the UK, attracting 50 million visitors annually. Paris Baguette Westfield features marble countertops, metal frames in the brand’s signature blue color, and wood finish, with the modern look accentuating the refined brand image. The Westfield store serves a diverse range of products including sandwiches, pastries, and cakes that have been well received by the UK and other European markets, creating unique experiences for both local customers and international visitors.

Wayne Stevenson, the owner of Paris Baguette’s first two franchise stores in the UK, said, “I am excited to be opening in a second location, as my first Paris Baguette in Canary Wharf has made its mark in the local community since its opening last year. What I have learned is that Paris Baguette leads the field in quality and innovation. I look forward to seeing Paris Baguette becoming a household name here.”

Paris Baguette launched in the UK in 2022, with a back-to-back opening of two sites in Battersea Power Station and Kensington High Street. In mid-December this year, the bakery-café chain is scheduled to open its fifth location and third franchise store in the UK, near Portobello Market, the setting for the movie Notting Hill, kicking its franchise business into high gear.

A Paris Baguette spokesperson said, “Building on the success of the first franchise store in the UK, we are adding two more franchise stores here. We are committed to enhancing brand awareness and competitiveness in Europe, where bread is a staple food, to take the lead in shaping the global bakery market.”

Paris Baguette made its initial foray into the global market in 2004 and has opened 700 stores in 15 countries over the past two decades across the US, Canada, France, the UK, Singapore, Vietnam, Indonesia, Malaysia, the Philippines, Cambodia, Thailand, Laos, Brunei, and Mongolia.

L&C Bio’s ‘Re2O’ Emerges as a Leading K-Medical Tour Procedure Within One Year of Launch

By
Advertorial Desk
-

– Surging global demand drives rapid adoption across domestic and international medical sectors –

SEONGNAM, South Korea, Dec. 2, 2025 /PRNewswire/ — L&C Bio (KOSDAQ: 290650, Co-CEOs Hwan-Chul Lee and Jae-Ho Lee), a leading company in human tissue–based regenerative medicine, announced that its premium regenerative solution Re2O (ReCM, ECM: Extra Cellular Matrix) has rapidly emerged as a signature K-Medical tour procedure among international customers within just one year of its launch. Re2O is demonstrating robust sales growth and rapidly expanding its market presence among international visitors to Korea, playing a significant role in the ongoing success of the medical tourism industry. The product’s growing demand emphasizes its position as a preferred choice for consumers seeking advanced skincare solutions during their visit. Furthermore, Re2O is gaining substantial momentum in key markets such as China, Japan, and Southeast Asia, highlighting its broadening influence and strong commercial potential across the region.

Premium regenerative solution Re2O(ReCM, ECM: Extra Cellular Matrix)
Premium regenerative solution Re2O(ReCM, ECM: Extra Cellular Matrix)

This growth is particularly remarkable considering that Re2O had relatively low brand recognition only six months ago. Dermatology and plastic surgery clinics, as well as major university hospitals across Korea, have recently accelerated adoption of Re2O, leading to an explosive increase in appointment inquiries from overseas patients. Demand for Re2O is rapidly expanding across global markets, supported by strong sales growth and increasing market presence.

Momentum has further intensified following presentations at international academic congresses. After Korean medical professionals gave presentations at Korea Derma and PRS Korea in October and November, interest from overseas clinicians surged dramatically. This global exposure has triggered a sharp increase in inquiries from international buyers and clinics, fueling worldwide word-of-mouth.

Dr. Sung-Min Noh, CEO and Director of Benjamin Clinic, stated, “Recently, there has been a growing interest and increasing inquiries from overseas patients visiting Korea regarding Re2O, highlighting its rising popularity and expanding demand among international visitors.” He added, “Foreign patients typically cannot visit Korea frequently or undergo multiple repeat sessions like domestic patients. Re2O offers immediate yet long-lasting results, making it the ideal solution for overseas customers—and this naturally drives international word-of-mouth.”

Due to rapidly rising domestic and global demand, Re2O is experiencing temporary supply shortages. The company explained, “Orders are far exceeding our initial forecasts, creating short-term supply tightness. However, we are responding quickly by expanding production facilities and operating a two-shift manufacturing system.” The company also noted that while partial shortages may continue into the first half of next year, it is continuously enhancing production efficiency to ensure stable supply for both domestic and international customers.

L&C Bio plans to further strengthen its production and quality competitiveness in line with growing global demand for K-Medical. The company will continue introducing innovative products that elevate Korea’s global presence in the medical and regenerative medicine sectors.

AODocs Recognized in Gartner® Innovation Guide for Generative AI Knowledge Management Apps

By
Advertorial Desk
-

ATLANTA, Dec. 2, 2025 /PRNewswire/ — AODocs announced today it has been recognized as an Emerging Specialist in the Gartner® Innovation Guide for Generative AI Knowledge Management Apps. We believe AODocs’ inclusion reinforces the company’s position in AI-driven knowledge management and intelligent document workflows.

AODocs’ inclusion underscores its unique capability to bridge traditional document control with modern AI-powered knowledge retrieval, positioning it among the most advanced vendors in this fast-growing market.

The report explores the evolving landscape of AI knowledge management apps and general productivity solutions, offering insights into how these innovations can help clients increase productivity, reduce costs, and enhance customer experience.

“Many companies struggle to move their AI agents from pilot to production, and a solid document management foundation is critical to making that transition successful,” said Stéphan Donzé, CEO and Founder of AODocs. “Without proper control, context, and governance over enterprise content, AI agents often use information sources that are obsolete or incorrect. AODocs provides that essential foundation to ensure organizations can deploy AI with confidence while maintaining security, compliance, and full traceability.”

We believe the recognition comes on the heels of product and business momentum for AODocs. Earlier this year, the company was named a High Performer in G2’s Reports for Enterprise Content Management (ECM) and Cloud Content Collaboration.

Gartner subscribers can read the Gartner® Innovation Guide for Generative AI Knowledge Management Apps here.

Gartner Disclaimer

Gartner, Innovation Guide for Generative AI Knowledge Management Apps, Marko Sillanpaa, Justin Tung, Stephen Emmott, Darin Stewart, 13 November 2025

GARTNER is a trademark of Gartner, Inc. and its affiliates.

Gartner does not endorse any company, vendor, product, or service depicted in its publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner publications consist of the opinions of Gartner’s business and technology insights organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this publication, including any warranties of merchantability or fitness for a particular purpose.

About AODocs

AODocs is a leading enterprise document management platform that transforms how organizations manage, process, and secure their business-critical documents. Founded in 2012, AODocs provides an AI-powered, cloud-native alternative to legacy document management systems, enabling organizations to maintain control while improving collaboration and accelerating productivity gains. Headquartered in Atlanta with offices in Paris, London, and San Francisco, AODocs is committed to helping enterprises get more value from their enterprise data, files, and content.

Learn more at www.aodocs.com

 

Cellid Announces Two New Reference Designs for Next-Generation AR Glasses

By
Advertorial Desk
-

 Cutting-edge wireless AR glasses enabled by proprietary optical technology and the latest waveguide innovations

TOKYO, Dec. 2, 2025 /PRNewswire/ — Cellid Inc., a developer of displays and spatial recognition engines for next-generation AR glasses, today announced two new reference designs (verification models) for augmented reality (AR) glasses: a green monochrome and a full-color model.

Of these two models, the monochrome green model features the latest plastic waveguide (display lens for AR glasses), which Cellid has successfully mass-produced for the first time globally, while the full-color model features a glass waveguide. Both models are wireless, offer excellent design, and are lightweight glasses-style AR devices, making them suitable for a wide range of scenarios, from promoting Digital Transformation (DX) in companies to everyday use.


High brightness, High visibility, Stable performance and Application-specific design
The two newly announced models were created by combining the latest technology developed through Cellid’s AR glasses initiatives with the extensive product development expertise of each partner company. This enables both models to meet the needs of domestic and international customers as AR glasses applications continue to diversify. These models combine a stylish design that revolutionizes the image of conventional AR glasses with high practicality for a wide range of applications.

All models feature binocular AR displays with a 30° field of view (FOV), providing high visibility and a natural viewing experience both indoors and outdoors. Information is displayed clearly thanks to Micro-LED projectors with a maximum brightness of 3000 nits. Both models also use the latest plastic and glass waveguides independently developed by Cellid, delivering a combination of light weight and excellent optical performance.

■ Main Features of the Two Models
Green Monochrome Model ― Simple Entry Model
Equipped with a high-performance Alif E7 Processor and the latest plastic waveguide, the green monochrome model also includes a 5-megapixel camera and 802.11ax Wi-Fi, making it well-suited for AI-enabled and networked applications.

CPU: Alif E7 Processor
Display: Micro LED (Green) VGA 640×480 (60Hz) (single color green)
Camera: 5M pixels
Wi-Fi: 802.11ax (2.4/5GHz)                                        

Full-Color Model ― Next-Generation Full-Color Model for High-End Applications
Featuring a glass waveguide, the full-color model delivers exceptional image quality through both high resolution and high brightness. It is equipped with a 12-megapixel camera and supports Wi-Fi 7, making it ideal for cutting-edge AR projects and XR platform development.

CPU: Qualcomm AR1 + GX8002
Display: Micro LED (RGB) 500 x 380 (Full Color)
Camera: 12MP
Wi-Fi: 802.11ax (2.4/5GHz)
*Full-color model availability scheduled for January 2026

Upcoming Event Participation
Cellid plans to participate in the following event. Experience our latest reference designs and various AR solutions:

January 6–9, 2026 CES 2026 (https://www.ces.tech/)
*Exhibition content and displayed products may vary depending on the event.

Comment from Satoshi Shiraga, CEO, Cellid
The two reference designs announced as next-generation AR glasses were developed based on Cellid’s accumulated technology and user feedback. They combine the latest optical technology with a stylish yet practical design, envisioned for use across a wide range of scenarios from daily life to professional applications. AR technology is now entering the stage of societal implementation. Particularly for waveguide technology, which is essential to AR glasses, the balance between optical performance, design, durability, mass-producibility, and cost efficiency is paramount. To meet these demands, Cellid, as one of the few companies capable of in-house manufacturing of waveguides using both glass and plastic materials, is advancing product development tailored to specific applications. Simultaneously, we are focusing on research and development of software and hardware technologies to optimize power efficiency, display technologies, and collaborative development of application cases across diverse industries. Cellid, guided by the philosophy of “realizing information tools that are closer to people and dramatically more convenient,” will continue collaborating with domestic and international partner companies to advance the deployment across diverse fields. We aim to expand the possibilities of AR glasses and realize richer augmented reality experiences.

About Cellid  
Cellid specializes in developing advanced AR glass display modules, focusing on waveguides and spatial recognition engines for next-generation devices. Leveraging unique optical simulation and proprietary production technologies, Cellid has developed display modules as thin and lightweight as standard eyeglass lenses, delivering clear images and one of the world’s largest fields of view for waveguides. Additionally, Cellid offers industry-specific solutions powered by spatial recognition technologies such as Cellid SLAM. By integrating cutting-edge AR display hardware with real-world spatial recognition software, Cellid is driving the “Blending of Physical and Digital World,” making exceptional information tools more accessible, practical, and convenient for users worldwide.

TP Receives Frost & Sullivan’s 2025 African Company of the Year Recognition for Excellence in the Outsourcing Industry

By
Advertorial Desk
-

TP recognized for advancing Africa’s outsourcing landscape through its strategic integration of technology, emotional intelligence, and sustainable growth initiatives.

SAN ANTONIO, Dec. 2, 2025 /PRNewswire/ — Frost & Sullivan is pleased to announce that global digital services leader TP has been recognized with the 2025 African Company of the Year Recognition in the outsourcing industry for its outstanding achievements in digital transformation, operational excellence, and customer-centric innovation. This recognition underscores TP’s leadership in integrating human expertise and empathy with advanced technology to deliver measurable business outcomes, drive sustainable growth, and transform the African outsourcing ecosystem through scalable, high-value services.

Frost & Sullivan evaluates companies through a rigorous benchmarking process across two core dimensions: visionary innovation & performance and customer execution. TP excelled in both, demonstrating its ability to align strategic initiatives with market demand while executing them with consistency, efficiency, and scale.

“Through a forward-looking blend of GenAI, emotional intelligence, and hyper-automation, TP enables brands to scale personalization, shorten resolution times, and gain predictive insight into customer behavior and operational performance. These capabilities are applicable as part of a unified architecture that balances automation with human touch, differentiating from competing solutions that do so in isolation,” said Bernardin Arnason, Industry Director, Frost & Sullivan.

Guided by a long-term growth strategy focused on digital innovation, local partnership, and sustainable ecosystem development, TP demonstrates exceptional agility in a rapidly evolving market. By embedding itself within Africa’s dynamic technology and service delivery landscape, the company continues to strengthen its regional footprint while aligning its capabilities with global outsourcing trends.

Innovation remains central to TP’s vision. Its unified architecture safely orchestrates AI, experts and technology at scale to create seamless, emotionally attuned customer interactions. This model delivers enhanced customer care that is simpler, faster, and safer for the world’s biggest brands and their customers.

TP’s strong commitment to inclusive growth further distinguishes it in the market. Through its deep engagement with national stakeholders—such as partnerships in Kenya to digitize public services—the company plays an active role in modernizing Africa’s service economy. Its people-first approach, combined with robust infrastructure investments, enables TP to deliver high-quality, multilingual support while creating meaningful local employment opportunities.

Frost & Sullivan commends TP for setting a new standard in competitive strategy, execution, and market responsiveness. The company’s vision, technology roadmap, and inclusive operating model are redefining the outsourcing industry across Africa—building an agile, innovation-driven framework that supports sustainable economic growth and strengthens Africa’s role in the global delivery ecosystem.

Each year, Frost & Sullivan presents the Company of the Year Recognition to organizations that demonstrate outstanding strategy development and implementation, resulting in measurable improvements in market share, customer satisfaction, and competitive positioning. The recognition honors forward-thinking companies that are reshaping their industries through innovation, strategic excellence, and sustainable impact.

Frost & Sullivan’s Best Practices recognitions identify companies across regional and global markets for their superior performance in leadership, technological innovation, customer service, and strategic development. Industry analysts evaluate market participants through comprehensive interviews, analyses, and extensive secondary research to identify best practices that advance industry standards.

Frost & Sullivan Best Practices Recognition

Frost & Sullivan’s Best Practices Recognitions honor companies across regional and global markets that exhibit exceptional achievement and consistent excellence in areas such as leadership, technological innovation, customer experience, and strategic product development. Each recognition is the result of a rigorous analytical process in which Frost & Sullivan industry experts benchmark performance through comprehensive interviews, deep-dive analysis, and extensive secondary research. The goal is to identify true best-in-class organizations that are driving transformative growth and setting new industry standards.
Contact us: Start the discussion.

Contact:
Ashley Shreve
E: ashley.weinkauf@frost.com 

ABOUT TP GROUP 
TP is a global leader in digital business services which consistently seeks to blend the best of advanced technology with human empathy to deliver enhanced customer care that is simpler, faster, and safer for the world’s biggest brands and their customers. The Group’s comprehensive, AI-powered service portfolio ranges from front office customer care to back-office functions, including operations consulting and high-value digital transformation services. It also offers a range of specialized services such as collections, interpreting and localization, visa and consular services, and recruitment process outsourcing services. The teams of multilingual, inspired, and passionate experts and advisors, spread in close to 100 countries, as well as the Group’s local presence allows it to be a force of good in supporting communities, clients, and the environment.

For more information: www.tp.com.

1...1,6111,6121,613...6,448Page 1,612 of 6,448